Post-earnings recap
Reported
Mon, Nov 5, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report shows that Amicus Therapeutics is struggling, particularly with its EPS significantly missing expectations. The stock's reaction, down 1.22%, reflects investor concerns about the company's current performance and lack of guidance for future quarters. Without clear direction from management, uncertainty may linger for investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.84 | N/A | -213.14% |
| Revenue | N/A | N/A | N/A |
Management's tone was defensive, indicating they are facing challenges without providing clear direction. The lack of guidance leaves uncertainty for investors.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company acknowledged challenges but did not elaborate on future strategies.